New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

SIMPLE SUMMARY: Neuroendocrine carcinoma of the pancreas is a highly aggressive form of neuroendocrine tumor associated with poor survival and increasing occurrence. GP-2250 is an emergent substance showing antineoplastic properties, especially in combination with Gemcitabine. This study was the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchholz, Marie, Strotmann, Johanna, Majchrzak-Stiller, Britta, Hahn, Stephan, Peters, Ilka, Horn, Julian, Müller, Thomas, Höhn, Philipp, Uhl, Waldemar, Braumann, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179328/
https://www.ncbi.nlm.nih.gov/pubmed/35681665
http://dx.doi.org/10.3390/cancers14112685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179328/
https://www.ncbi.nlm.nih.gov/pubmed/35681665
http://dx.doi.org/10.3390/cancers14112685

Ejemplares similares